NCT05169580 is a Phase 1 clinical trial of Pociredir oral capsule(s) in Sickle Cell Disease, sponsored by Fulcrum Therapeutics.

Who is sponsoring NCT05169580?

NCT05169580 is sponsored by Fulcrum Therapeutics.

What drugs are being tested in NCT05169580?

Interventions in NCT05169580: Pociredir oral capsule(s).

What condition does NCT05169580 study?

NCT05169580 studies Sickle Cell Disease, Sickle Cell Anemia.

Is NCT05169580 still recruiting?

NCT05169580 is currently completed. Last updated 12 February 2026.

Last reviewed 2026-02-12 · How we verify

NCT05169580

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

Completed Phase 1 Last updated 12 February 2026

What this trial tests

Phase 1 trial testing Pociredir oral capsule(s) in Sickle Cell Disease in 45 participants. Completed in 20 January 2026.

Timeline

13 December 2021

Primary endpoint
20 January 2026

20 January 2026

Quick facts

Lead sponsor	Fulcrum Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	13 December 2021
Primary completion	20 January 2026
Estimated completion	20 January 2026
Sites	18 locations across South Africa, United States, Nigeria

Drugs / interventions tested

Pociredir oral capsule(s) — full drug profile →

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sickle Cell Anemia — all drugs for Sickle Cell Anemia →

Sponsor

Fulcrum Therapeutics — full company profile →

Who can join

Adults 18 to 65, any sex, with Sickle Cell Disease or Sickle Cell Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
Bao Q, Kumar A, Wu D, Zhou J. · · 2024 · cited 14× · PMID 38642703 · DOI 10.1016/j.drudis.2024.103986
Hydroxyurea in the sickle cell disease modern era.
Riley C, Kraft WK, Miller R. · · 2024 · cited 6× · PMID 39135533 · DOI 10.1080/17512433.2024.2390915
Annual Sickle Cell & Thalassaemia Conference (ASCAT) ‐ October 2024
· 2024
EHA2024 Hybrid Congress
· 2024
Abstract Book for the 27th Congress of the European Hematology Association
· 2022
P1498: INHIBITION OF POLYCOMB REPRESSIVE COMPLEX 2 THROUGH EED INDUCES FETAL HEMOGLOBIN IN HEALTHY AND SICKLE CELL DISEASE MODELS
Stuart B, Bruno P, Polioudakis D, Roth M, et al · · 2022

Verify or expand the search:

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Fulcrum Therapeutics trials

Trials by the same sponsor.

NCT07401823 — Open-Label Extension Study to Pioneer Study 6058-SCD-101 · Phase 2 · enrolling by invitation
NCT05397470 — Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) · Phase 3 · terminated
NCT05002231 — Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets · Phase 1 · completed
NCT04586985 — Safety, Tolerability and Pharmacokinetics of FTX-6058 · Phase 1 · completed
NCT04511819 — Losmapimod Safety and Efficacy in COVID-19 · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05169580 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fulcrum Therapeutics
Last refreshed: 12 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05169580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing